Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Oncology Today with Dr Neil Love · Dr. Neil Love
October 25, 202445m 46s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here.